These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 26509262)
1. Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. Lee E; Ha S; Logan SK PLoS One; 2015; 10(10):e0141589. PubMed ID: 26509262 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003 [TBL] [Abstract][Full Text] [Related]
3. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096 [TBL] [Abstract][Full Text] [Related]
4. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer. Patel R; Brzezinska EA; Repiscak P; Ahmad I; Mui E; Gao M; Blomme A; Harle V; Tan EH; Malviya G; Mrowinska A; Loveridge CJ; Rushworth LK; Edwards J; Ntala C; Nixon C; Hedley A; Mackay G; Tardito S; Sansom OJ; Leung HY Cancer Res; 2020 Feb; 80(3):576-590. PubMed ID: 31719098 [TBL] [Abstract][Full Text] [Related]
5. p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer. Clark EL; Hadjimichael C; Temperley R; Barnard A; Fuller-Pace FV; Robson CN PLoS One; 2013; 8(1):e54150. PubMed ID: 23349811 [TBL] [Abstract][Full Text] [Related]
6. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322 [TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872 [TBL] [Abstract][Full Text] [Related]
8. Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. Khurana N; Sikka SC Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027362 [TBL] [Abstract][Full Text] [Related]
9. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Wan X; Liu J; Lu JF; Tzelepi V; Yang J; Starbuck MW; Diao L; Wang J; Efstathiou E; Vazquez ES; Troncoso P; Maity SN; Navone NM Clin Cancer Res; 2012 Feb; 18(3):726-36. PubMed ID: 22298898 [TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells. Nakata D; Koyama R; Nakayama K; Kitazawa S; Watanabe T; Hara T Prostate; 2017 Jun; 77(9):955-961. PubMed ID: 28397338 [TBL] [Abstract][Full Text] [Related]
12. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Wang G; Wang J; Sadar MD Cancer Res; 2008 Dec; 68(23):9918-27. PubMed ID: 19047173 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Wnt/β-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. Atawia IM; Kushwaha PP; Verma S; Lin S; Shankar E; Abdel-Gawad O; Gupta S Mol Carcinog; 2023 Sep; 62(9):1312-1324. PubMed ID: 37232341 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of androgen receptor and β-catenin activity in prostate cancer. Lee E; Madar A; David G; Garabedian MJ; Dasgupta R; Logan SK Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15710-5. PubMed ID: 24019458 [TBL] [Abstract][Full Text] [Related]
15. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. Amir AL; Barua M; McKnight NC; Cheng S; Yuan X; Balk SP J Biol Chem; 2003 Aug; 278(33):30828-34. PubMed ID: 12799378 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis. He Y; Mi J; Olson A; Aldahl J; Hooker E; Yu EJ; Le V; Lee DH; Kim WK; Robins DM; Geradts J; Sun Z Oncogene; 2020 Apr; 39(16):3276-3291. PubMed ID: 32089544 [TBL] [Abstract][Full Text] [Related]
17. Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Chen M; Feuerstein MA; Levina E; Baghel PS; Carkner RD; Tanner MJ; Shtutman M; Vacherot F; Terry S; de la Taille A; Buttyan R Mol Cancer; 2010 Apr; 9():89. PubMed ID: 20420697 [TBL] [Abstract][Full Text] [Related]
18. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. Whitworth H; Bhadel S; Ivey M; Conaway M; Spencer A; Hernan R; Holemon H; Gioeli D PLoS One; 2012; 7(6):e38950. PubMed ID: 22761715 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer. Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858 [TBL] [Abstract][Full Text] [Related]